SCHEMBL4333859

SCHEMBL4333859

CCC(=O)COCC(=O)CC

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.56
ALDH1A1 P00352 7/20 0.39
FFAR3 O14843 1/20 0.39
SOAT1 P35610 1/20 0.36
CES2 O00748 1/20 0.32
LMNA P02545 1/20 0.32
HSD17B10 Q99714 1/20 0.32
TSHR P16473 3/20 0.32
ALOX15 P16050 1/20 0.30
MGAM O43451 1/20 0.30
GAA P10253 1/20 0.30
SI P14410 1/20 0.30
MGAM2 Q2M2H8 1/20 0.30
PTGS1 P23219 1/20 0.30
MGMT P16455 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14562572 0.89 FFAR3 (0.45) TDP1ALDH1A1FFAR3SOAT1TSHR
SCHEMBL14234014 0.89 CES2 (0.46) TDP1ALDH1A1FFAR3SOAT1CES2
SCHEMBL15315157 0.89 TDP1 (0.45) TDP1ALDH1A1FFAR3SOAT1
SCHEMBL5986397 0.88
SCHEMBL19510342 0.87 TDP1 (0.43) TDP1ALDH1A1FFAR3HSD17B10
SCHEMBL15867022 0.87 TDP1 (0.43) TDP1ALDH1A1FFAR3
SCHEMBL13936054 0.85
SCHEMBL13167778 0.84 TSHR (0.42) TDP1ALDH1A1LMNAHSD17B10TSHR
SCHEMBL30736083 0.83
SCHEMBL8379389 0.83

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1919812-A Refining method for hexafluoromethylene aromatic compound SHANGHAI 3F NEW MATERIAL CO LT (CN) 2007-02-28 CN claimed
EP-0879259-B2 PREPARATION OF DOUBLE METAL CYANIDE-CATALYZED POLYOLS BY CONTINUOUS ADDITION OF STARTER BAYER ANTWERPEN NV (BE) 2006-04-12 EP claimed
US-12522619-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2026-01-13 US disclosed
EP-4463462-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2024-11-20 EP disclosed
CN-118715231-A Complement factor inhibitors and uses thereof 安尼艾克松股份有限公司 2024-09-27 CN disclosed
CN-114213264-B Beta-polyether amine, synthesis method thereof and aliphatic polyurea coating containing beta-polyether amine 江苏朝晖化工有限公司 2024-04-19 CN disclosed
US-20230265109-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2023-08-24 US disclosed
US-20230265109-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2023-08-24 US disclosed
US-20230265109-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2023-08-24 US disclosed
WO-2023137166-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. (US) 2023-07-20 WO disclosed
WO-2023137166-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. (US) 2023-07-20 WO disclosed
CN-114213264-A Beta-polyether amine, synthetic method thereof and aliphatic polyurea coating containing beta-polyether amine 江苏朝晖化工有限公司 2022-03-22 CN disclosed
CN-205115338-U Production line by synthetic raspberry ketone of nature identical anisyl aldehyde GUANGXI WANSHAN SPICE CO LTD 2016-03-30 CN disclosed
CN-105198720-A Production line for synthesizing raspberry ketone from natural equivalent anisic aldehyde GUANGXI WANSHAN SPICE CO LTD 2015-12-30 CN disclosed
CN-104541388-A Electrochemical cells comprising electrolyte additives, and methods for making and using the same DU PONT 2015-04-22 CN disclosed
US-8273787-B2 Activated cytotoxic compounds for attachment to targeting molecules for the treatment of mammalian disease conditions ONCONOVA THERAPEUTICS, INC (US) 2012-09-25 US disclosed
US-20100022615-A1 ACTIVATED CYTOTOXIC COMPOUNDS FOR ATTACHMENT TO TARGETING MOLECULES FOR THE TREATMENT OF MAMMALIAN DISEASE CONDITIONS ONCONOVA THERAPEUTICS, INC (US) 2010-01-28 US disclosed
EP-2058383-A1 PENTAFLUOROBUTANE COMPOSITION Kaneko Chemical Co., Ltd. (JP) 2009-05-13 EP disclosed
CN-1919812-A Refining method for hexafluoromethylene aromatic compound SHANGHAI 3F NEW MATERIAL CO LT (CN) 2007-02-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022615-A1 ACTIVATED CYTOTOXIC COMPOUNDS FOR ATTACHMENT TO TARGETING MOLECULES FOR THE TREATMENT OF MAMMALIAN DISEASE CONDITIONS CD40, TNFRSF9, NGFR TDP1 3309/4885ALDH1A1 2628/4885FFAR3 1580/4885
US-20230265109-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 TDP1 1413/4885ALDH1A1 653/4885FFAR3 1215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.